Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Aneurysm III: Interprofessional Care01:26

Aneurysm III: Interprofessional Care

Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

MAD-MT Score: A Tool to Optimize Patient Selection for Mechanical Thrombectomy in Distal Vessel Occlusions.

Stroke·2026
Same author

Neuroradiology Leads NIH Funding Among Clinician Diagnostic Radiologists: A 14-Year National Analysis.

AJNR. American journal of neuroradiology·2026
Same author

MRI of Lesions Growing Along the Pituitary Stalk.

Radiographics : a review publication of the Radiological Society of North America, Inc·2026
Same author

Flow diversion for intracranial aneurysms in patients with sickle cell disease.

The neuroradiology journal·2026
Same author

Stroke Severity and Functional Benefit of Thrombectomy in Acute M2 Middle Cerebral Artery Occlusion: A Multicenter Cohort Study.

Neurology·2026
Same author

Perfusion imaging abnormalities in acute cerebral venous sinus thrombosis: A case series.

The neuroradiology journal·2026
Same journal

Loss of Pericytic Integrin-β1 Exacerbates Blood-Brain Barrier Damage and Hemorrhagic Brain Injury.

Stroke·2026
Same journal

Threshold Effects, Cognitive Decline, and Longitudinal Changes in White Matter Hyperintensity Volume.

Stroke·2026
Same journal

PREVENT Equations: Implications for Stroke Prevention.

Stroke·2026
Same journal

Defining the Therapeutic Ceiling of Endovascular Thrombectomy in Large-Core Stroke: Beyond the Limits of ASPECTS.

Stroke·2026
Same journal

Adjunctive Normobaric Hyperoxia With Endovascular Thrombectomy for Acute Stroke at 6 to 24 Hours: A Phase IIb Randomized Trial.

Stroke·2026
See all related articles

Related Experiment Video

Updated: May 22, 2026

Arterial Pouch Microsurgical Bifurcation Aneurysm Model in the Rabbit
06:11

Arterial Pouch Microsurgical Bifurcation Aneurysm Model in the Rabbit

Published on: May 14, 2020

GLP-1 Receptor Agonist Use Is Associated With Lower Risk of Intracranial Aneurysm Rupture and Rupture Severity.

Huanwen Chen1,2, Matthew K McIntyre3, Jay Kakadiya4

  • 1Department of Neurology (H.C.), University of Maryland Medical Center, Baltimore.

Stroke
|May 21, 2026
PubMed
Summary
This summary is machine-generated.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) significantly reduced the risk of unruptured intracranial aneurysm (UIA) rupture by 48%. GLP-1RA use also correlated with less severe outcomes, including reduced hemorrhage and vasospasm, in patients experiencing aneurysm rupture.

Keywords:
endothelial cellsglycemic controlintracranial aneurysmsubarachnoid hemorrhagevasoconstriction

Related Experiment Videos

Last Updated: May 22, 2026

Arterial Pouch Microsurgical Bifurcation Aneurysm Model in the Rabbit
06:11

Arterial Pouch Microsurgical Bifurcation Aneurysm Model in the Rabbit

Published on: May 14, 2020

Area of Science:

  • Neurology
  • Cardiovascular Research
  • Pharmacology

Background:

  • Unruptured intracranial aneurysms (UIAs) affect up to 5% of the population, with rupture leading to subarachnoid hemorrhage.
  • Glucagon-like peptide-1 receptor agonists (GLP-1RAs) possess anti-inflammatory and vasculoprotective properties.
  • The impact of GLP-1RAs on UIA stability and rupture outcomes remains uninvestigated.

Purpose of the Study:

  • To evaluate the association between GLP-1RA use and the risk of UIA rupture.
  • To assess the impact of GLP-1RA use on the severity of outcomes following aneurysm rupture.

Main Methods:

  • A retrospective cohort study utilized the TriNetX US Collaborative Network (2016-2024).
  • Cohort 1 comprised patients with newly diagnosed, untreated UIAs; Cohort 2 included patients who experienced aneurysm rupture.
  • Propensity score matching balanced covariates; GLP-1RA exposure was defined based on timing relative to diagnosis or rupture.

Main Results:

  • In untreated UIAs (Cohort 1), GLP-1RA use was linked to a 48% reduction in rupture hazard over 5 years (HR, 0.52; P<0.001).
  • Among ruptured aneurysms (Cohort 2), prerupture GLP-1RA use correlated with significantly lower rates of intraparenchymal hemorrhage (17.4% vs 33.6%; P<0.001) and intraventricular hemorrhage (10.1% vs 23.5%; P<0.001).
  • GLP-1RA users also showed reduced rates of vasospasm (10.7% vs 24.2%; P=0.002) and numerically lower 30-day mortality (9.4% vs 14.1%; P=0.21).

Conclusions:

  • GLP-1RA use is associated with a substantial decrease in UIA rupture risk.
  • In cases of rupture, GLP-1RA use is linked to attenuated clinical and radiographic severity.
  • Findings suggest potential neuroprotective and vascular stabilizing effects of GLP-1RAs in UIA patients.